Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
$MRK
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
74,000
ISIN
US58933Y1055
Website
Merck & Co. Metrics
BasicAdvanced
$205B
11.85
$6.88
0.40
$3.20
3.97%
Price and volume
Market cap
$205B
Beta
0.4
52-week high
$128.73
52-week low
$73.31
Average daily volume
16M
Dividend rate
$3.20
Financial strength
Current ratio
1.41
Quick ratio
0.827
Long term debt to equity
69.182
Total debt to equity
71.992
Dividend payout ratio (TTM)
45.54%
Interest coverage (TTM)
19.06%
Profitability
EBITDA (TTM)
28,812.25
Gross margin (TTM)
77.07%
Net profit margin (TTM)
27.27%
Operating margin (TTM)
38.19%
Effective tax rate (TTM)
13.48%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
13.81%
Return on equity (TTM)
39.29%
Valuation
Price to earnings (TTM)
11.851
Price to revenue (TTM)
3.225
Price to book
4.24
Price to tangible book (TTM)
24.9
Price to free cash flow (TTM)
12.102
Free cash flow yield (TTM)
8.26%
Free cash flow per share (TTM)
673.61%
Dividend yield (TTM)
3.93%
Forward dividend yield
3.97%
Growth
Revenue change (TTM)
4.10%
Earnings per share change (TTM)
667.14%
3-year revenue growth (CAGR)
5.80%
10-year revenue growth (CAGR)
4.44%
3-year earnings per share growth (CAGR)
7.18%
10-year earnings per share growth (CAGR)
5.98%
3-year dividend per share growth (CAGR)
5.73%
10-year dividend per share growth (CAGR)
5.83%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Bulls say / Bears say
Merck's acquisition of EyeBio for $3 billion in July 2024 enhances its ophthalmology pipeline, potentially driving future revenue growth. (Financial Times)
The company's strong dividend yield of approximately 4.18% and a 14-year history of increasing dividends make it attractive to income-focused investors. (MarketBeat)
Merck's robust cash flow generation, with cash from operations reaching $16.86 billion in 2023, provides financial flexibility for R&D and strategic acquisitions. (VStar)
Merck's pause in Gardasil shipments to China due to weak demand has led to a 41% drop in sales, negatively impacting revenue forecasts. (Reuters)
The impending patent expiration of Keytruda in 2028 poses a significant risk to Merck's revenue, as the drug currently generates substantial sales. (Financial Times)
Merck's stock has underperformed, with a year-to-date decline of 19.93% and a 37.70% drop over the past 12 months, reflecting investor concerns. (PortfoliosLab)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions
GlobeNewsWire·5 hours ago
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
GlobeNewsWire·2 days ago
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $205B as of July 18, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 11.85 as of July 18, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of July 18, 2025, the dividend rate is $3.2 and the yield is 3.97%. Merck & Co. has a payout ratio of 45.54% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.